• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

氟考昔诱导的肺纤维化罕见病例

A Rare Case of Flavocoxid-Induced Pulmonary Fibrosis.

作者信息

Drekolias Dimitrios, Gadela Naga Vaishnavi, Krupka Philip, Broess Jennifer, Jacob Jason

机构信息

Internal Medicine, University of Connecticut, Farmington, USA.

Internal Medicine, Rush University, Chicago, USA.

出版信息

Cureus. 2020 Aug 8;12(8):e9617. doi: 10.7759/cureus.9617.

DOI:10.7759/cureus.9617
PMID:32923218
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7478690/
Abstract

Pulmonary fibrosis is a chronic progressive interstitial lung disease characterized by repetitive cycles of epithelial cell injury and dysregulated repair. Although most cases of pulmonary fibrosis are idiopathic, a detailed history that includes medications, comorbidities, tobacco use, environmental exposures, and family history should be taken to rule out secondary etiology. We present a case of flavocoxid-induced pulmonary toxicity which progressed from hypersensitivity pneumonitis to pulmonary fibrosis even after discontinuation of the offending drug.

摘要

肺纤维化是一种慢性进行性间质性肺疾病,其特征为上皮细胞损伤和修复失调的反复循环。虽然大多数肺纤维化病例是特发性的,但应详细询问病史,包括用药情况、合并症、吸烟史、环境暴露史和家族史,以排除继发性病因。我们报告一例由黄氧化素引起的肺毒性病例,即使停用致病药物后,仍从过敏性肺炎进展为肺纤维化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fd5/7478690/f8cf7b8253ed/cureus-0012-00000009617-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fd5/7478690/117d3a025459/cureus-0012-00000009617-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fd5/7478690/145465df1844/cureus-0012-00000009617-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fd5/7478690/f8cf7b8253ed/cureus-0012-00000009617-i03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fd5/7478690/117d3a025459/cureus-0012-00000009617-i01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fd5/7478690/145465df1844/cureus-0012-00000009617-i02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7fd5/7478690/f8cf7b8253ed/cureus-0012-00000009617-i03.jpg

相似文献

1
A Rare Case of Flavocoxid-Induced Pulmonary Fibrosis.氟考昔诱导的肺纤维化罕见病例
Cureus. 2020 Aug 8;12(8):e9617. doi: 10.7759/cureus.9617.
2
Can CT distinguish hypersensitivity pneumonitis from idiopathic pulmonary fibrosis?计算机断层扫描(CT)能区分过敏性肺炎和特发性肺纤维化吗?
AJR Am J Roentgenol. 1995 Oct;165(4):807-11. doi: 10.2214/ajr.165.4.7676971.
3
Hypersensitivity pneumonitis due to flavocoxid: are corticosteroids necessary?因氟考昔所致的超敏性肺炎:是否需要使用皮质类固醇?
Conn Med. 2013 Feb;77(2):87-90.
4
[Pathologic study of diffuse pulmonary interstitial fibrosis caused by chronic hypersensitivity pneumonitis].[慢性过敏性肺炎所致弥漫性肺间质纤维化的病理学研究]
Zhonghua Bing Li Xue Za Zhi. 2009 Feb;38(2):86-90.
5
Pathology of hypersensitivity pneumonitis.过敏性肺炎的病理学
Curr Opin Pulm Med. 2008 Sep;14(5):440-54. doi: 10.1097/MCP.0b013e3283043dfa.
6
Chronic hypersensitivity pneumonitis: important considerations in the work-up of this fibrotic lung disease.慢性过敏性肺炎:这种纤维化肺病检查中的重要注意事项。
Curr Opin Pulm Med. 2015 Mar;21(2):171-7. doi: 10.1097/MCP.0000000000000137.
7
Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis.加拿大肺纤维化注册研究中的基线特征和合并症。
BMC Pulm Med. 2019 Nov 27;19(1):223. doi: 10.1186/s12890-019-0986-4.
8
[Hypersensitivity pneumonitis and idiopathic pulmonary fibrosis - case report].[过敏性肺炎与特发性肺纤维化——病例报告]
Pol Merkur Lekarski. 2018 Mar 27;44(261):152-156.
9
Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study.特发性肺纤维化患者的慢性过敏性肺炎:一项前瞻性病例队列研究。
Lancet Respir Med. 2013 Nov;1(9):685-94. doi: 10.1016/S2213-2600(13)70191-7. Epub 2013 Oct 21.
10
GOAL: multicenter, open-label, post-marketing study of flavocoxid, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin.目的:一项关于 flavocoxid(一种新型植物源双重途径抑制剂抗炎药)的多中心、开放性、上市后研究。
Curr Med Res Opin. 2010 May;26(5):1055-63. doi: 10.1185/03007991003694522.

本文引用的文献

1
Causality assessment: A brief insight into practices in pharmaceutical industry.因果关系评估:对制药行业实践的简要洞察。
Perspect Clin Res. 2013 Oct;4(4):233-6. doi: 10.4103/2229-3485.120173.
2
Hypersensitivity pneumonitis due to flavocoxid: are corticosteroids necessary?因氟考昔所致的超敏性肺炎:是否需要使用皮质类固醇?
Conn Med. 2013 Feb;77(2):87-90.
3
Flavocoxid and hypersensitivity pneumonitis.黄酮氧化合物与过敏性肺炎
Chest. 2011 Sep;140(3):827-828. doi: 10.1378/chest.11-0632.
4
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.特发性肺纤维化:诊断和管理的循证指南(美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会联合发布)
Am J Respir Crit Care Med. 2011 Mar 15;183(6):788-824. doi: 10.1164/rccm.2009-040GL.
5
Using the medical food flavocoxid [corrected] in managing osteoarthritis.使用医用食品黄酮醇来治疗骨关节炎。 [已修正]
J Pain Palliat Care Pharmacother. 2011;25(1):49-54. doi: 10.3109/15360288.2010.548446.
6
The safety of flavocoxid, a medical food, in the dietary management of knee osteoarthritis. flavocoxid,一种医学食品,在膝骨关节炎饮食管理中的安全性。
J Med Food. 2009 Oct;12(5):1143-8. doi: 10.1089/jmf.2008.0244.
7
Flavocoxid, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, blunts pro-inflammatory phenotype activation in endotoxin-stimulated macrophages.Flavocoxid,环氧化酶和 5-脂氧合酶的双重抑制剂,可减弱脂多糖刺激的巨噬细胞中促炎表型的激活。
Br J Pharmacol. 2009 Aug;157(8):1410-8. doi: 10.1111/j.1476-5381.2009.00322.x.
8
Chronic hypersensitivity pneumonitis: differentiation from idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia by using thin-section CT.慢性过敏性肺炎:通过薄层CT与特发性肺纤维化和非特异性间质性肺炎进行鉴别
Radiology. 2008 Jan;246(1):288-97. doi: 10.1148/radiol.2453061881.
9
Drug-induced pulmonary fibrosis.药物性肺纤维化
Saudi Med J. 2004 Jun;25(6):700-6.
10
A method for estimating the probability of adverse drug reactions.一种估算药物不良反应概率的方法。
Clin Pharmacol Ther. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154.